{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:05:55Z","timestamp":1792195555698,"version":"4.4.0"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.addr.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:52:17Z","timestamp":1610056337000},"page":"71-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"special_numbering":"C","title":["Recombinant protein vaccines, a proven approach against coronavirus pandemics"],"prefix":"10.1016","volume":"170","author":[{"given":"Jeroen","family":"Pollet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.001_bb0005","series-title":"Coronavirus: Sputnik V vaccine rushed out to wary Russians","author":"Rainsford","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0010","article-title":"China drugmaker fact-checks claim that its leading COVID vaccine is 97% effective","author":"McGregor","year":"2020","journal-title":"Fortune"},{"key":"10.1016\/j.addr.2021.01.001_bb0015","series-title":"As U.K. Begins Vaccinations, A Glimpse of Life After Covid","author":"Mueller","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0020","series-title":"Canada Authorizes Use Of Pfizer COVID-19 Vaccine","author":"Dwyer","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0025","series-title":"DRAFT Landscape of COVID-19 Candidate Vaccines","author":"WHO","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0030","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0035","series-title":"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0040","series-title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With\/Without Matrix-M Adjuvant","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0045","article-title":"Sanofi-GSK covid-19 vaccine is set back by lab mistake","author":"Dalton","year":"2020","journal-title":"Wall Street J."},{"key":"10.1016\/j.addr.2021.01.001_bb0050","series-title":"SCB-2019 as COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0055","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","author":"Liang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0060","series-title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0070","series-title":"Monovalent Recombinant COVID19 Vaccine (COVAX19)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0075","series-title":"Vaxine and Medytox \u2013 COVAX-19\u00ae","author":"Genengnews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0080","series-title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0085","series-title":"Biological E\u2019s Novel Covid-19 Vaccine of SARS-CoV-2 for Protection Against Covid-19 Disease","author":"CTRI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0090","article-title":"SARS-CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","author":"Pollet","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0095","article-title":"Cloning, expression and biophysical characterization of a yeast-expressed recombinant SARS-CoV-2 receptor binding domain COVID-19 vaccine candidate","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0100","author":"RPCEC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0105","series-title":"Soberana is Cuba\u2019s, The First Candidate Vaccine Against COVID-19 in Latin America and the Caribbean, Granma - The OFFICIAL VOICE OF THE COMMUNIST PARTY OF CUBA CENTRAL COMMITTEE","author":"Morales","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0110","series-title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0115","series-title":"Clinical Study of Recombinant Novel Coronavirus Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0120","series-title":"A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial of the Effectiveness and Safety of Inoculation of Recombinant New Coronavirus Vaccine (CHO cells) in the Prevention of COVID-19 in People 18 Years and Older","author":"CHICTR","year":"2020"},{"issue":"7830","key":"10.1016\/j.addr.2021.01.001_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0130","series-title":"Recombinant COVID-19 Vaccine (Sf9 cells) Phase II Clinical Trial","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0135","series-title":"Randomized Double Blind, Placebo Controlled Phase I Trial for Anti Novel Coronavirus Pneumonia (COVID-19) Recombinant Vaccine (Sf9)","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0140","series-title":"COVAXX \u2013 UB-612","author":"Genetic_Engineering&Biotechnology_News","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0145","series-title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0150","series-title":"Study of the Safety, Reactogenicity and Immunogenicity of \u201cEpiVacCorona\u201d Vaccine for the Prevention of COVID-19 (EpiVacCorona)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0155","series-title":"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)","author":"Clinicaltrials_gov","year":"2020"},{"issue":"1","key":"10.1016\/j.addr.2021.01.001_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2021.01.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory diagnosis of COVID-19: current issues and challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.addr.2021.01.001_bb0185","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6483","key":"10.1016\/j.addr.2021.01.001_bb0195","first-page":"1260","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0205","first-page":"92","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Trans. Targ. Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0225","series-title":"WIPO","article-title":"Chimeric molecules and uses thereof","author":"Chappell","year":"2018"},{"key":"10.1016\/j.addr.2021.01.001_bb0230","series-title":"Molecular Clamp Stabilised Spike Protein For Protection Against SARS- CoV-2","author":"Watterson","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0240","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.01.001_bb0245","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","author":"Kuo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0250","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0255","article-title":"Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C\/B' HIV-1 candidate vaccine","volume":"5","author":"Vasan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0260","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0270","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0275","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.addr.2021.01.001_bb0295","article-title":"Development of unique Australian COVID-19 vaccine halted","author":"Norville","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0305","series-title":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","author":"PipelineReviews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/136419","article-title":"Comparative evaluation of recombinant protein production in different biofactories: the green perspective","volume":"2014","author":"Merlin","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/pr7080476","article-title":"Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing","volume":"7","author":"Puetz","year":"2019","journal-title":"Processes"},{"key":"10.1016\/j.addr.2021.01.001_bb0325","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/pbp.14.8","article-title":"Biopharmaceutical protein production by Saccharomyces cerevisiae: current state and future prospects","volume":"2","author":"Huang","year":"2014","journal-title":"Pharm. Bioprocess."},{"key":"10.1016\/j.addr.2021.01.001_bb0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0355","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba((R))): a review in active immunization against invasive meningococcal group b disease in individuals aged 10-25 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs: Clin. Immunother. Biopharm. Gene Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-420070-8.00012-X","article-title":"Protein expression-yeast","volume":"536","author":"Nielsen","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2021.01.001_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/S1679-45082013000400027","article-title":"Vaccination against human papillomavirus","volume":"11","author":"Mello","year":"2013","journal-title":"Einstein"},{"key":"10.1016\/j.addr.2021.01.001_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nprot.2008.213","article-title":"Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology","volume":"4","author":"Jacobs","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2021.01.001_bb0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0395","series-title":"Coronavirus|U.S.-Based Baylor College of Medicine Ties Up with India\u2019s Biological E for COVID-19 Vaccine","author":"PTI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0400","series-title":"Biological E. Limited Starts Phase I\/II Clinical Trial of its COVID-19 Vaccine Candidate","author":"Dynavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0405","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0410","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0415","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fbioe.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0420","first-page":"20","article-title":"Recombinant glycoprotein E of varicella zoster virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures","author":"Norden","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0425","first-page":"2156","article-title":"Production of human beta interferon in insect cells infected with a baculovirus expression vector","volume":"3","author":"Smith","year":"1983","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2021.01.001_bb0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0435","first-page":"47","article-title":"Trends in the development of baculovirus expression vectors","volume":"6","author":"Luckow","year":"1988","journal-title":"Bio\/Technology"},{"key":"10.1016\/j.addr.2021.01.001_bb0440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/bit.260361108","article-title":"High-level recombinant protein production in bioreactors using the baculovirus-insect cell expression system","volume":"36","author":"Caron","year":"1990","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2021.01.001_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btpr.1842","article-title":"Protein production using the baculovirus-insect cell expression system","volume":"30","author":"Contreras-Gomez","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.addr.2021.01.001_bb0450","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/138945007782151360","article-title":"Protein N-glycosylation in the baculovirus-insect cell system","volume":"8","author":"Shi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2021.01.001_bb0455","series-title":"BAT Working on Potential COVID-19 Vaccine through US Bio-tech Subsidiary","author":"BAT","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0460","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1104\/pp.124.3.927","article-title":"Production of recombinant proteins in tobacco guttation fluid","volume":"124","author":"Komarnytsky","year":"2000","journal-title":"Plant Physiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0465","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4161\/21645515.2014.980199","article-title":"New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74","volume":"11","author":"Pearson","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0470","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/21645515.2015.1036207","article-title":"Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine","volume":"11","author":"Seid","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0475","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biotechadv.2009.11.008","article-title":"Tobacco, a highly efficient green bioreactor for production of therapeutic proteins","volume":"28","author":"Tremblay","year":"2010","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2021.01.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4216060","article-title":"A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals","volume":"2019","author":"Owczarek","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0485","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1387-2656(07)13004-0","article-title":"Preparation of recombinant vaccines","volume":"13","author":"Soler","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.addr.2021.01.001_bb0490","series-title":"Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry","author":"FDA","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0495","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-018-0305-2","article-title":"Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action","volume":"14","author":"Shardlow","year":"2018","journal-title":"Allergy Asthma Clin. Immunol.: Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0500","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0505","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0515","series-title":"Developing a Low-Cost and Accessible COVID-19 Vaccine for Global Health","author":"Hotez","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0520","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O'Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0530","series-title":"Adjuvanted Flu Vaccine","author":"CDC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0535","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3","article-title":"Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis","volume":"31","author":"Dupuis","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0540","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0545","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O'Hagan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res.: Off. J. Eur. Histam. Res. Soc. \u2026 [et al.]"},{"key":"10.1016\/j.addr.2021.01.001_bb0555","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"15","article-title":"Development of the CpG adjuvant 1018: A case study","author":"Campbell","year":"2016"},{"key":"10.1016\/j.addr.2021.01.001_bb0560","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0565","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix\u2122 and Arepanrix\u2122","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0580","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0585","first-page":"49","article-title":"Induction of virus-specific immunity by iscoms","volume":"92","author":"Osterhaus","year":"1998","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.addr.2021.01.001_bb0590","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0595","series-title":"Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers","author":"Clinicaltrials_gov","year":"2011"},{"key":"10.1016\/j.addr.2021.01.001_bb0600","series-title":"A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant","author":"Clinicaltrials_gov","year":"2014"},{"key":"10.1016\/j.addr.2021.01.001_bb0605","series-title":"Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1\u2122 Adjuvants In Clinically-Stable Older Adults","author":"Clinicaltrials_gov","year":"2017"},{"key":"10.1016\/j.addr.2021.01.001_bb0610","series-title":"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","author":"Clinicaltrials_gov","year":"2019"},{"key":"10.1016\/j.addr.2021.01.001_bb0615","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0620","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0625","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0630","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0635","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.0141-9838.2004.00685.x","article-title":"Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity","volume":"26","author":"MacDonald","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0640","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0645","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-422X-7-9","article-title":"An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2021.01.001_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.addr.2021.01.001_bb0655","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0660","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2021.01.001_bb0665","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0670","first-page":"2145","article-title":"Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells","volume":"63","author":"Bonnotte","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0680","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijbiomac.2020.05.239","article-title":"A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2","volume":"160","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2021.01.001_bb0685","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0690","series-title":"Vaxart's oral COVID-19 Tablet Vaccine to Enter Clinical Trials","author":"Arthur","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0695","series-title":"Merck Looks to Lower Barriers to COVID-19 Vaccination with Oral Approach","author":"Eaton","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0700","series-title":"Chinese Covid-19 Vaccine Candidate Becomes First Nasal Spray to Start Clinical Trial","author":"Simin","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0705","series-title":"Nasal Spray Vaccine for Covid-19","author":"ClinicalTrialsArena","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0710","series-title":"Single-Dose Intranasal COVID-19 Vaccine","author":"Altimmune","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0715","series-title":"FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","author":"University_of_Wisconsin, UW\u2013Madison","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0720","series-title":"Fundamentals and Applications of Controlled Release Drug Delivery","author":"Siepmann","year":"2012"},{"key":"10.1016\/j.addr.2021.01.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8303648","article-title":"Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines","volume":"2019","author":"Criscuolo","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.addr.2021.01.001_bb0730","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0735","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.vaccine.2006.06.043","article-title":"Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant","volume":"24","author":"Hutcheon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0740","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2005.04.037","article-title":"Preparation of coated nanoparticles for a new mucosal vaccine delivery system","volume":"299","author":"Borges","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.01.001_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-020-0190-9","article-title":"New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes","volume":"5","author":"Amacker","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2021.01.001_bb0755","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0760","series-title":"Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine","author":"Kempers","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0765","series-title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0770","series-title":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","author":"Novavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0775","series-title":"COVID-19 Tracker: Warp Speed Chief Eyes Timeline for Pfizer, Moderna, AZ Shot Data; FDA can Reveal Safety info If Vaccine Makers Don't, Official Says, Fierce_Pharma","author":"Sagonowsky","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0780","series-title":"Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals\u2019 COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant","author":"Biospace","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0785","series-title":"Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program","author":"Clover_Biopharma","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0795","article-title":"Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment","author":"Malladi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0800","article-title":"A vaccine displaying a trimeric influenza-a ha stem protein on capsid-like particles elicits potent and long-lasting protection in mice","volume":"8","author":"Thrane","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0805","series-title":"COVID-19 cVLP Vaccine Demonstrated as Effective in Mice","author":"de Jongh","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0810","series-title":"ExpreS2ion Announces Successful Manufacturing of the cVLP COVID-19 Vaccine and Further Positive Updates","author":"Frandsen","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0815","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12026-013-8468-x","article-title":"Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases","volume":"57","author":"Strbo","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcpa.2014.01.004","article-title":"The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models","volume":"151","author":"van den Brand","year":"2014","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.addr.2021.01.001_bb0825","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/CVI.00455-14","article-title":"Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome","volume":"21","author":"Selinger","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0830","article-title":"Induction of SARS-CoV-2 protein S-specific CD8+T cells in the lungs of gp96-Ig-S vaccinated mice","author":"Fisher","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0835","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01083-20","article-title":"COVID-19 vaccines: \u201cWarp Speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0840","series-title":"Correlates and Disparities of COVID-19 Vaccine Hesitancy","author":"Callaghan","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0845","article-title":"Protein-based Covid-19 vaccines could overshadow rivals","author":"King","year":"2020","journal-title":"Chem. World"},{"key":"10.1016\/j.addr.2021.01.001_bb0850","series-title":"Pfizer, Moderna's Coronavirus Shot Rollouts Could Freeze Up, Experts Say, Citing Cold-storage Needs","author":"Blankenship","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0855","article-title":"Safety and immunogenicity of heterologous and homologous two dose regimens of Ad26- and MVA-vectored ebola vaccines: a randomized, controlled phase 1 study","author":"Goldstein","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0860","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0865","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0870","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.001_bb0875","article-title":"Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults","author":"Sadoff","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0880","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An Mrna vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0885","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv: Preprint Server Health Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0890","series-title":"After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine","author":"Robbins","year":"2020"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:55:46Z","timestamp":1759208146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":178,"alternative-id":["S0169409X21000016"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202011.0558.v1","asserted-by":"object"}]},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}